|
2023 Conference Publication The interplay of IL-23, probiotic and pathobiont bacteria in the pathogenesis of ileitis and spondyloarthritis in the SKG mouse modelBergot, Anne-Sophie, Cai, Benjamin, Giri, Rabina, Cameron, Amy, Duggan, Emily, Lim, Kai, Rehaume, Linda, Morrison, Mark, Begun, Jakob and Thomas, Ranjeny (2023). The interplay of IL-23, probiotic and pathobiont bacteria in the pathogenesis of ileitis and spondyloarthritis in the SKG mouse model. 2023 Australian Rheumatology Association (ARA) 63rd Annual Scientific Meeting, Hobart, TAS, Australia, 6–9 May 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Journal Article Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liverAlabbas, Saleh Y., Giri, Rabina, Oancea, Iulia, Davies, Julie, Schreibner, Veronika, Florin, Timothy H. and Begun, Jakob (2023). Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver. Journal of Gastroenterology and Hepatology, 38 (4), 609-618. doi: 10.1111/jgh.16102 |
|
2023 Journal Article Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialFeagan, Brian G, Sands, Bruce E, Sandborn, William J, Germinaro, Matthew, Vetter, Marion, Shao, Jie, Sheng, Shihong, Johanns, Jewel, Panés, Julián, Tkachev, Alexander, Kalimullina, Dilara, Petryka, Robert, Osipenko, Marina, Tsarynna, Nataliia, Bilianskyi, Leonid, Kleczkowski, Dariusz, Yurkiv, Andrii, Woynarowski, Marek, Abrahamovych, Orest, Ivanishyn, Olha, Rydzewska, Grazyna, Kierkus, Jaroslaw, Petrova, Elina, Vasilevskaya, Olga, Afanasieva, Halyna, Francesconi, Carlos, Leszczyszyn, Jaroslaw, Bunkova, Elena, Platonov, Dmitry ... for the VEGA Study Group (2023). Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. The Lancet Gastroenterology and Hepatology, 8 (4), 307-320. doi: 10.1016/S2468-1253(22)00427-7 |
|
2023 Journal Article Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancerLyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127 |
|
2023 Journal Article An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitisMortlock, Sally, Lord, Anton, Montgomery, Grant, Zakrzewski, Martha, Simms, Lisa A, Krishnaprasad, Krupa, Hanigan, Katherine, Doecke, James D, Walsh, Alissa, Lawrance, Ian C, Bampton, Peter A, Andrews, Jane M, Mahy, Gillian, Connor, Susan J, Sparrow, Miles P, Bell, Sally, Florin, Timothy H., Begun, Jakob, Gearry, Richard B and Radford-Smith, Graham L. (2023). An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. Journal of Crohn's and Colitis, 17 (2), 277-288. doi: 10.1093/ecco-jcc/jjac121 |
|
2023 Conference Publication Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trialPudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. OXFORD: OXFORD UNIV PRESS. |
|
2023 Conference Publication Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC CohortAn, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0793 |
|
2023 Conference Publication Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohortAn, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744 |
|
2023 Conference Publication Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel diseaseMoniruzzaman, M., Rewatkar, P., Begun, J. and Popat, A. (2023). Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0167 |
|
2023 Conference Publication Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trialPudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0543 |
|
2022 Conference Publication Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 ResultsPanes, Julian, Loftus, Edward, Lacerda, Ana, Peyrin-Biroulet, Laurent, D’Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid, Liu, Jianzhong, Dubcenco, Elena, Mohamed, Mohamed-Eslam, Feng, Tian and Colombel, Jean-Frederic (2022). Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results. 2022 Advances in Inflammatory Bowel Diseases Annual Meeting, Orlando, FL United States, 5-7 December 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.14309/01.ajg.0000897656.25080.34 |
|
2022 Journal Article Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosisMalloy, Reuben, Fernandes, Richard, Begun, Jakob and An, Yoon-Kyo (2022). Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 15 (12) 252140, e252140. doi: 10.1136/bcr-2022-252140 |
|
2022 Conference Publication Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium CohortAn,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard, Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953 |
|
2022 Conference Publication Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic RemissionPudipeddi, Aviv, Fung, Caroline, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon, Begun, Jakob, Connor, Susan, Chetwood, John, Paramsothy, Sudarshan and Leong, Rupert (2022). Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission. International Digestive Disease Forum (IDDF), Hong Kong, China, 2-4 September 2022. London, United Kingdom: BMJ Group. doi: 10.1136/gutjnl-2022-IDDF.207 |
|
2022 Conference Publication Ocrelizumab-induced medically refractory fulminant colitis requiring colectomyMalloy, R., Fernandes, R., Begun, J. and An, Y-K (2022). Ocrelizumab-induced medically refractory fulminant colitis requiring colectomy. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, International Convention Centre Sydney (ICC Sydney), Sydney, NSW, Australia, 9 - 11 September 2022. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.15953 |
|
2022 Journal Article MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axisSheng, Yong H., Davies, Julie M., Wang, Ran, Wong, Kuan Yau, Giri, Rabina, Yang, Yuanhao, Begun, Jakob, Florin, Timothy H., Hasnain, Sumaira Z. and McGuckin, Michael A. (2022). MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis. Cellular and Molecular Gastroenterology and Hepatology, 14 (4), 789-811. doi: 10.1016/j.jcmgh.2022.06.010 |
|
2022 Journal Article GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infectionLamba, M., Tiwari, N., Remedios, M., Begun, J., Christensen, B., Bollipo, S. and Devereaux, B. (2022). GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection. Journal of Gastroenterology and Hepatology (Australia), 37 (7), 1400-1401. doi: 10.1111/jgh.15873 |
|
2022 Journal Article Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialSands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B, Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Mihaly, Emese, Panaccione, Remo, Scherl, Ellen, Shchukina, Oksana B, Sandborn, William J, Afzali, Anita, Aitova, Lilia, Aldeguer i Mante, Xavier, Altorjay, István, Argüelles Arias, Federico, Armuzzi, Alessandro, Augustyn, Monika, Bafutto, Mauro, Barrio, Jesus, Begun, Jakob ... Zdena, Zadorova (2022). Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet, 399 (10342), 2200-2211. doi: 10.1016/S0140-6736(22)00688-2 |
|
2022 Journal Article The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisCheon, Jae Hee, Paridaens, Kristine, Awadhi, Sameer Al, Begun, Jakob, Fullarton, John R, Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Dignass, Axel U and Travis, Simon PL (2022). The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 21 (1), 161-167. doi: 10.5217/ir.2022.00006 |
|
2022 Journal Article Secreted NF-κB suppressive microbial metabolites modulate gut inflammationGiri, Rabina, Hoedt, Emily C., Khushi, Shamsunnahar, Salim, Angela A., Bergot, Anne-Sophie, Schreiber, Veronika, Thomas, Ranjeny, McGuckin, Michael A., Florin, Timothy H., Morrison, Mark, Capon, Robert J., Ó Cuív, Páraic and Begun, Jakob (2022). Secreted NF-κB suppressive microbial metabolites modulate gut inflammation. Cell Reports, 39 (2) 110646, 110646. doi: 10.1016/j.celrep.2022.110646 |
